|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-12-23
|
|
pubmed:abstractText |
Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiological constraints on growth and survival. To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small molecule inhibitors for a host of other kinases that are implicated in cancer and other diseases. Herein we discuss the current challenges in the field, such as designing selective inhibitors and developing strategies to overcome resistance mutations. This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1474-1768
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
28-39
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19104514-Allosteric Regulation,
pubmed-meshheading:19104514-Antineoplastic Agents,
pubmed-meshheading:19104514-Binding Sites,
pubmed-meshheading:19104514-Drug Delivery Systems,
pubmed-meshheading:19104514-Drug Design,
pubmed-meshheading:19104514-Drug Discovery,
pubmed-meshheading:19104514-Drug Resistance, Neoplasm,
pubmed-meshheading:19104514-Humans,
pubmed-meshheading:19104514-Models, Molecular,
pubmed-meshheading:19104514-Neoplasm Proteins,
pubmed-meshheading:19104514-Neoplasms,
pubmed-meshheading:19104514-Protein Binding,
pubmed-meshheading:19104514-Protein Conformation,
pubmed-meshheading:19104514-Protein Kinase Inhibitors,
pubmed-meshheading:19104514-Protein Kinases,
pubmed-meshheading:19104514-Signal Transduction,
pubmed-meshheading:19104514-Substrate Specificity
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Targeting cancer with small molecule kinase inhibitors.
|
|
pubmed:affiliation |
Dana-Farber Cancer Institute, Department of Cancer Biology, Harvard Medical School, Boston, Massachusetts 02115, USA.
|
|
pubmed:publicationType |
Journal Article,
Review
|
